Equity Profile

AUPH

Aurinia Pharmaceuticals Inc.

Health CareBiotechnology$2.0B

Jul30Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Aurinia Pharmaceuticals Inc. is a biotechnology company focused on developing therapies for kidney diseases and other serious conditions....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will help gauge the company's financial health this quarter.

$0.24

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

$80M

Wall Street expectations, options signals, track record, and call prep available with Pro.

AUPH Q2-2026 Earnings Preview

Context

Company Snapshot

Aurinia Pharmaceuticals Inc. is a biotechnology company focused on developing therapies for kidney diseases and other serious conditions. With a market cap of $2 billion, its innovations are crucial in addressing unmet medical needs in the health care sector.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+142.91%

Avg Stock Reaction

+0.41%

Last Quarter Recap

In Q1-2026, Aurinia reported an EPS of $0.25, significantly beating estimates. However, the stock experienced a decline of 6.80% the following day.

Management Promises & Guidance

Continued focus on expanding its product pipeline.
Commitment to increasing market presence in kidney disease treatments.
Plans to enhance investor communication regarding future developments.

Expectations

Wall Street Expectations

Analysts are cautiously optimistic about Aurinia's upcoming earnings, expecting solid EPS and revenue figures. The market is keen to see if the company can maintain its momentum from the previous quarter.

Bull Case

If Aurinia beats EPS and revenue estimates, it could signal strong demand for its products and bolster investor confidence.

Bear Case

Conversely, if the company fails to meet expectations, it may raise concerns about its growth trajectory and lead to a negative market reaction.

Key Metrics to Watch

EPS

$0.24

Earnings per share is a key indicator of profitability and will help gauge the company's financial health this quarter.

Revenue

$80M

Revenue figures will provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Aurinia's EPS meet or exceed the consensus estimate of $0.24?

A strong EPS figure could validate the company's growth strategy and reassure investors about its profitability.

What specific revenue figures can Aurinia provide to support its growth narrative?

Revenue performance will be critical in assessing market demand and the effectiveness of its sales strategies.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Aurinia's ability to capitalize on recent advancements in kidney disease treatments, potentially leading to higher revenue than expected.

Supporting Evidence

The company's recent product developments have not been fully reflected in analyst estimates.

Aurinia's strong historical performance suggests it may continue to exceed expectations.

Options pricing indicates a significant move, which could signal that traders anticipate a positive surprise.

Key Risk

If Aurinia's revenue exceeds $86M, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The upcoming earnings report is pivotal in determining whether Aurinia can maintain its positive trajectory in a competitive market.

Bull Confirmed If

An EPS of $0.29 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $0.21 would raise concerns about the company's ability to sustain growth.

Pre-Earnings Positioning

Options Market

Implied Move

±23.81%

Historical Avg

±5.3%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±23.8% while AUPH has averaged ±5.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

38.5%

Calls (23K)P/C Ratio: 0.02Puts (400)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Aurinia beats expectations, history suggests the stock could rise by about 1.03% on the following day, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss could lead to a decline of around 1.44%, reflecting disappointment and potential concerns about future growth.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline advancements.
2Details on sales performance in key markets.
3Management's outlook on competitive pressures.
4Insights into customer feedback on recent product launches.
5Guidance on future revenue expectations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

PreviewView

Jul27

ARLPBMO

Company Snapshot

Aurinia Pharmaceuticals Inc. is a biotechnology company focused on developing therapies for kidney diseases and other serious conditions....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will help gauge the company's financial health this quarter.

$0.24

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

$80M

Wall Street expectations, options signals, track record, and call prep available with Pro.

AUPH Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+142.91%

Avg Stock Reaction

+0.41%

Last Quarter Recap

In Q1-2026, Aurinia reported an EPS of $0.25, significantly beating estimates. However, the stock experienced a decline of 6.80% the following day.

Management Promises & Guidance

Continued focus on expanding its product pipeline.
Commitment to increasing market presence in kidney disease treatments.
Plans to enhance investor communication regarding future developments.

Expectations

Wall Street Expectations

Bull Case

If Aurinia beats EPS and revenue estimates, it could signal strong demand for its products and bolster investor confidence.

Bear Case

Conversely, if the company fails to meet expectations, it may raise concerns about its growth trajectory and lead to a negative market reaction.

Key Metrics to Watch

EPS

$0.24

Earnings per share is a key indicator of profitability and will help gauge the company's financial health this quarter.

Revenue

$80M

Revenue figures will provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Aurinia's EPS meet or exceed the consensus estimate of $0.24?

A strong EPS figure could validate the company's growth strategy and reassure investors about its profitability.

What specific revenue figures can Aurinia provide to support its growth narrative?

Revenue performance will be critical in assessing market demand and the effectiveness of its sales strategies.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Aurinia's ability to capitalize on recent advancements in kidney disease treatments, potentially leading to higher revenue than expected.

Supporting Evidence

The company's recent product developments have not been fully reflected in analyst estimates.

Aurinia's strong historical performance suggests it may continue to exceed expectations.

Options pricing indicates a significant move, which could signal that traders anticipate a positive surprise.

Key Risk

If Aurinia's revenue exceeds $86M, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The upcoming earnings report is pivotal in determining whether Aurinia can maintain its positive trajectory in a competitive market.

Bull Confirmed If

An EPS of $0.29 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $0.21 would raise concerns about the company's ability to sustain growth.

Pre-Earnings Positioning

Options Market

Implied Move

±23.81%

Historical Avg

±5.3%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±23.8% while AUPH has averaged ±5.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

38.5%

Calls (23K)P/C Ratio: 0.02Puts (400)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Aurinia beats expectations, history suggests the stock could rise by about 1.03% on the following day, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss could lead to a decline of around 1.44%, reflecting disappointment and potential concerns about future growth.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline advancements.
2Details on sales performance in key markets.
3Management's outlook on competitive pressures.
4Insights into customer feedback on recent product launches.
5Guidance on future revenue expectations.